Salud financiera de hoja de balance de Blueprint Medicines
Salud financiera controles de criterios 4/6
Blueprint Medicines tiene un patrimonio de los accionistas total de $130.6M y una deuda total de $680.4M, lo que sitúa su ratio deuda-patrimonio en 521%. Sus activos y pasivos totales son $1.0B y $918.6M respectivamente.
Información clave
521.0%
Ratio deuda-patrimonio
US$680.44m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$710.64m |
| Patrimonio | US$130.61m |
| Total pasivo | US$918.64m |
| Activos totales | US$1.05b |
Actualizaciones recientes sobre salud financiera
Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?
Apr 26
Is Blueprint Medicines (NASDAQ:BPMC) Weighed On By Its Debt Load?
Nov 20Is Blueprint Medicines (NASDAQ:BPMC) Using Debt Sensibly?
Jul 26Health Check: How Prudently Does Blueprint Medicines (NASDAQ:BPMC) Use Debt?
Apr 16Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt
Dec 12Here's Why We're Not Too Worried About Blueprint Medicines' (NASDAQ:BPMC) Cash Burn Situation
Nov 10Recent updates
Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?
Apr 26Risks To Shareholder Returns Are Elevated At These Prices For Blueprint Medicines Corporation (NASDAQ:BPMC)
Apr 05Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)
Feb 20Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Could Be 29% Below Their Intrinsic Value Estimate
Jan 08Subdued Growth No Barrier To Blueprint Medicines Corporation (NASDAQ:BPMC) With Shares Advancing 38%
Dec 18Is Blueprint Medicines (NASDAQ:BPMC) Weighed On By Its Debt Load?
Nov 20Is Blueprint Medicines (NASDAQ:BPMC) Using Debt Sensibly?
Jul 26Health Check: How Prudently Does Blueprint Medicines (NASDAQ:BPMC) Use Debt?
Apr 16Is Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 09Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt
Dec 12Need To Know: Analysts Just Made A Substantial Cut To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates
Nov 07Blueprint Medicines: Royalties Being Sold Allows For More Shots On Goal
Sep 15Blueprint to seek label expansion for systemic mastocytosis therapy after trial win
Aug 17Blueprint Medicines reports Q2 earnings miss; reaffirms FY22 guidance
Aug 02Blueprint to sell Ayvakit royalty for $250M upfront; Gavreto royalty for $175M upfront
Jun 30Time To Worry? Analysts Just Downgraded Their Blueprint Medicines Corporation (NASDAQ:BPMC) Outlook
Feb 17Here's Why We're Not Too Worried About Blueprint Medicines' (NASDAQ:BPMC) Cash Burn Situation
Nov 10Calculating The Intrinsic Value Of Blueprint Medicines Corporation (NASDAQ:BPMC)
Oct 15Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($808.4M) de BPMC superan a sus pasivos a corto plazo ($214.9M).
Pasivo a largo plazo: Los activos a corto plazo de BPMC ($808.4M) superan a sus pasivos a largo plazo ($703.7M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: BPMC tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de BPMC ha crecido de 0% a 521% en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: BPMC tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: Datos insuficientes para determinar si BPMC tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.